TTNP — Titan Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $5.52m
- $2.72m
- 25
- 24
- 55
- 26
Annual cashflow statement for Titan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.2 | -8.78 | -10.2 | -5.57 | -4.71 |
| Depreciation | |||||
| Non-Cash Items | -0.271 | 0.875 | 1.45 | -0.719 | -0.002 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.02 | -0.219 | 0.378 | -0.916 | 0.823 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -17.2 | -7.9 | -8.18 | -7.09 | -3.88 |
| Capital Expenditures | -0.54 | -0.023 | 0 | -0.002 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0.734 | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.54 | -0.023 | 0 | 0.732 | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.9 | 8.84 | 4.98 | 10 | -0.062 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.19 | 0.919 | -3.2 | 3.64 | -3.94 |